This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/5/1101    most recent ATVBAHA.107.140566v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zirlik, A. Articles by Schönbeck, U. Search for Related Content PubMed PubMed Citation Articles by Zirlik, A. Articles by Schönbeck, U.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1101.)
© 2007 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate Proinflammatory Functions of CD40L in Endothelial Cells

Andreas Zirlik; Udo Bavendiek; Peter Libby; Lindsey MacFarlane; Norbert Gerdes; Joanna Jagielska; Sandra Ernst; Masanori Aikawa; Hiroyasu Nakano; Erdyni Tsitsikov; Uwe Schönbeck

From Donald W. Reynolds Cardiovascular Research Center (A.Z., U.B., L.M., N.G., M.A., P.L., U.S.), Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass; Department of Cardiology (A.Z., S.E.), University of Freiburg, Germany; Department of Cardiology (U.B., J.J.), Hannover Medical School, Hannover, Germany; Department of Immunology (H.N.), Juntendo University, School of Medicine, Tokyo, Japan; Department of Immunology (E.T.), Children’s Hospital, Harvard Medical School, Boston, Mass; Cardiovascular Disease (U.S.), Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Conn.

Correspondence to Peter Libby, MD, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, NRB-741, Boston, MA 02115. E-mail plibby{at}rics.bwh harvard.edu.

Objective— Several lines of evidence implicate CD40 ligand (CD40L, CD154) as a mediator and marker of atherosclerosis. This study investigated the involvement of tumor necrosis factor receptor-associated factors (TRAFs) in CD40 signaling in endothelial cells (ECs) and their expression in atheromata and cells involved in atherogenesis.

Methods and Results— CD40L enhanced the basal expression of TRAF-1, -2, -3, and 6, but not TRAF-5 in ECs. TRAFs associated with CD40 on ligation by CD40L. Study of ECs from TRAF-1, -2, and -5-deficient mice demonstrated functional involvement of TRAFs in proinflammatory CD40 signaling. Whereas TRAF-1 deficiency enhanced CD40L-induced IL-6 and MCP-1 expression, TRAF-2 and TRAF-5 deficiency inhibited CD40L-inducible IL-6 but not MCP-1 expression. Gene silencing in human ECs further delineated functions of TRAFs in CD40 signaling. TRAF-3 silencing in ECs showed increased CD40L-induced IL-6, MCP-1, and IL-8 expression, whereas TRAF-6 silencing increased selectively CD40L-induced MCP-1 expression. Enhanced TRAF levels in atherosclerotic lesions further supports involvement of members of this family of signaling molecules in arterial disease.

Conclusions— These results implicate endothelial TRAF-1, -2, -3, -5, and -6 in CD40 signaling in atherogenesis, identifying these molecules as potential targets for selective therapeutic intervention.

This study tested the hypothesis that TRAF-1, -2, -3, -5, and -6 participate in CD40 signaling in ECs. TRAFs differentially mediated CD40L-induced IL-6, IL-8, and MCP-1 expression and atherosclerotic arteries overexpressed TRAFs, identifying these signaling molecules as potential therapeutic targets.

Key Words: atherosclerosis • CD40L • inflammation • signaling • TRAF

This article has been cited by other articles:

				M. M. P. C. Donners, L. Beckers, D. Lievens, I. Munnix, J. Heemskerk, B. J. Janssen, E. Wijnands, J. Cleutjens, A. Zernecke, C. Weber, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling Blood, May 1, 2008; 111(9): 4596 - 4604. [Abstract] [Full Text] [PDF]